Exact Sciences - EXAS Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.

12 Wall Street research analysts have issued 12 month price objectives for Exact Sciences' shares. Their EXAS share price forecasts range from $40.00 to $130.00. On average, they anticipate the company's stock price to reach $69.14 in the next year. This suggests a possible upside of 112.8% from the stock's current price.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.

Exact Sciences' stock was trading at $77.83 at the start of the year. Since then, EXAS stock has decreased by 58.3% and is now trading at $32.49.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXAS earnings forecast.

Exact Sciences Co. (NASDAQ:EXAS) released its earnings results on Tuesday, August, 2nd. The medical research company reported ($0.94) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.13. The medical research company earned $521.64 million during the quarter, compared to analysts' expectations of $496.75 million. Exact Sciences had a negative trailing twelve-month return on equity of 22.07% and a negative net margin of 37.90%.

Exact Sciences issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.98 billion-$2.02 billion, compared to the consensus revenue estimate of $2.02 billion.

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $32.49.

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $5.75 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis.

The company employs 6,500 workers across the globe.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.